Natco Pharma Limited announced today that it has launched a generic version of Sofosbuvir 400 mg / Velpatasvir 100 mg fixed dose combination in India. Sofosbuvir 400 mg / Velpatasvir 100 mg fixed dose combination is sold by Gilead Sciences, Inc., globally, under the brand name Epclusa.
Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic Hepatitis C virus (HCV) infection. Epclusa is a prescription medicine used to treat adults with chronic (lasting a long time) Hepatitis C (Hep C) genotype 1, 2, 3, 4, 5, or 6 infection with or without cirrhosis (compensated).
Natco will market Sofosbuvir 400 mg / Velpatasvir 100 mg under the brand name VELPANAT. Natco priced its generic medicine of VELPANAT at an MRP of INR 18,500/- for a bottle of 28 tablets in India. Natco has signed a nonexclusive licensing agreement with Gilead Sciences, Inc., to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries.